Company: LENZ
Filing Date: 2025-04-14
Form Type: 424B5
Source: 0001628280-25-017695
Chunk: 8

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-14
Form: 424B5
Chunk 8
---
8-K and amendments to these reports as soon as reasonably practicable after electronically filing or furnishing those reports to the SEC.

<div align='center'>S-4</div>

The Offering

| Common Stock Offered by Us                   |     | Shares of common stock having an aggregate offering price of up to $150,000,000.                                                                                                                                                                                                                                                                                                                              |
| Common Stock Outstanding After this Offering |     | Up to 6,521,739 shares, assuming sales at a price of $23.00 per share, which was the closing price of our common stock on Nasdaq on April 3, 2025. The actual number of shares issued will vary depending on the sales price under this offering.                                                                                                                                                             |
| Manner of Offering                           |     | “At the market” offering that may be made from time to time through our sales agent, TD Cowen. See “Plan of Distribution” on pageS-15of this prospectus supplement.                                                                                                                                                                                                                                           |
| Use of Proceeds                              |     | Our management will retain broad discretion regarding the allocation and use of the net proceeds from this offering. We currently intend to use the net proceeds from this offering, if any, for general corporate purposes and working capital, including for continued development and commercialization of LNZ100, subject to FDA approval. See “Use of Proceeds” on pageS-11of this prospectussupplement. |
| Risk Factors                                 |     | Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on pageS-7of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of certain factors that you should carefully consider before deciding to invest in shares of our common stock.                                       |
| Nasdaq Global Select Market symbol           |     | “LENZ”                                                                                                                                                                                                                                                                                                                                                                                                        |

The number of shares of common stock to be outstanding after this offering is based on 27,531,490 shares of common stock outstanding as of December 31, 2024 and excludes, in each case as of December 31, 2024: • 164,676 shares of our common stock issuable upon the exercise of warrants to purchase shares of our common stock outstanding as of December 31, 2024, with an exercise price of $10.64 per share; • 1,458,939 shares of our common stock issuable upon the exercise of outstanding options under the LENZ Therapeutics Operations, Inc